Three Things

June 2010
Pharmaceutical Representative;Jun2010, Vol. 40 Issue 6, p9
The article offers world news briefs related to pharmaceutical industry including a result from a poll from Capstrat that patients consult doctors first then to Google when it comes to health information and the move of AstraZeneca PLC to dismiss several employees as a result of entrusting more of the sales effort for Nexium medicine to a call center.


Related Articles

  • AstraZeneca.  // Formulary;Oct2000 Resource Guide, Vol. 35 Issue 10, p10 

    Features the AstraZeneca Pharmaceuticals LP, a pharmaceutical manufacturer. Medical focus areas of its research and development; Investment plans for worldwide pharmaceutical research and development; Best-performing pharmaceuticals.

  • AstraZeneca launches major investment programme.  // Life Science Today;Apr2001, Vol. 2 Issue 2, p5 

    Reports on pharmaceutical company AstraZeneca's investment on laboratories and office accommodation at its research and development site at Alderley Park in Cheshire, England. Inclusion of a DNA archive and genotyping center and a cell production facility; Other international business functions...

  • Cash in Hand. Branch Jr., Al // Pharmaceutical Executive;Mar2003, Vol. 23 Issue 3, p19 

    Reports that Astra Zeneca set aside multimillion dollars to settle claims over its prostate cancer treatment Zoladex. Study of the operations and practices of pharmaceutical companies.

  • New Science facility at Charnwood.  // Pharmaceutical Technology Europe;Nov2001, Vol. 13 Issue 11, p5 

    Announces the opening of a pharmaceutical development facility by AstraZeneca at its research and development site in Charnwood, Great Britain. Purpose of the facility; Comments from Doctor Tom McKillop, chief executive of AstraZeneca, on the facility.

  • The new blockbuster generation.  // Pharmaceutical Technology Europe;Sep2002, Vol. 14 Issue 9, p10 

    Reports the research and development pipelines of several pharmaceutical company in Great Britain. Sales of AstraZeneca cardiovascular drugs in the market; Patent expiries faced by the pharmaceutical industry; Factors contributing to the growth of the industry.

  • Clinical trial labels inspected for reliability. Abrams, Bernard // Packaging Digest;Mar2000, Vol. 37 Issue 3, p76 

    Reports on the actions taken by Astra-Zeneca Pharmaceutical's clinical trial division to ensure complete compliance of the United States Food and Drug Administration's requirements in labeling of medicines. Use of an electronic inspection system for thermal-transfer labels; Guidelines for...

  • AstraZeneca Aims for Lucrative Markets With Exanta and Crestor. Jarvis, Lisa // Chemical Market Reporter;7/23/2001, Vol. 260 Issue 4, p7 

    Focuses on the pharmaceutical products offered by AstraZeneca PLC to gain share in lucrative markets. Varied expectations on the impact of the company's Exanta on the market; Two promising oncology products by AstraZeneca; Reason behind the success of the company's Nexium.

  • AZ Upbeat Despite Lawsuits. Gopal, Kevin // Pharmaceutical Executive;Jan2002, Vol. 22 Issue 1, p23 

    Presents information on AstraZeneca which is facing a lawsuit to protect its Prilosec drug from generic competition in the United States (U.S.) as of January 2002. Market share of its Nexium ulcer medicine in the U.S.; Market share of its Symbicort drug in France; Drugs scheduled to be launched...

  • Be-spoke bike revolution.  // Employee Benefits;Aug2003, p12 

    Explores the tax-free bicycle scheme offered by pharmaceutical firm AstraZeneca. Three-year lease deal offered by the company to its employees.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics